Persistent Pulmonary Hypertension of the Newborn (PPHN) Malpractice

Normal Fetal Circulation vs. Neonatal Transition

Understanding PPHN requires understanding the normal circulatory transition that occurs at birth:

Fetal circulation: In the womb, the fetus does not use its lungs for gas exchange — oxygen comes from the placenta through the umbilical vein. The pulmonary blood vessels are constricted (high resistance), and most blood bypasses the lungs through two fetal channels: - Ductus arteriosus: A blood vessel connecting the pulmonary artery to the aorta, allowing blood to bypass the lungs. - Foramen ovale: An opening between the right and left atria of the heart, allowing blood to bypass the lungs.

Neonatal transition: At birth, when the baby takes its first breath, the pulmonary blood vessels dilate (resistance drops), blood flow to the lungs increases, and the ductus arteriosus and foramen ovale close (functionally, then anatomically over days to weeks). This allows blood to flow through the lungs for oxygenation.

In PPHN, this transition fails. The pulmonary blood vessels remain constricted, the ductus arteriosus and foramen ovale remain open, and blood continues to bypass the lungs — causing severe hypoxia. The baby appears cyanotic (blue) despite receiving supplemental oxygen.

Causes of PPHN

PPHN can be caused by a variety of factors:

• Meconium aspiration syndrome (MAS): The baby inhales meconium (first stool) mixed with amniotic fluid, causing inflammation and vasoconstriction in the lungs. MAS is a leading cause of PPHN.
• Respiratory distress syndrome (RDS): Premature babies with immature lungs can develop PPHN.
• Congenital diaphragmatic hernia (CDH): A structural abnormality where the diaphragm doesn't fully form, allowing abdominal organs to enter the chest and compress the lungs — causing underdeveloped lungs and PPHN.
• Perinatal asphyxia: Lack of oxygen during birth can cause PPHN.
• Maternal SSRI use: Selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy — especially after 20 weeks — have been associated with an increased risk of PPHN.
• Maternal NSAID use: Non-steroidal anti-inflammatory drugs (aspirin, ibuprofen) can cause premature closure of the ductus arteriosus, contributing to PPHN.
• Idiopathic: In some cases, no identifiable cause is found.
• Infection: Perinatal infections (chorioamnionitis, sepsis) can contribute to PPHN.
• Maternal diabetes: Associated with an increased risk of PPHN.

SSRI Use During Pregnancy and PPHN

One of the most significant developments in PPHN litigation involves the association between maternal SSRI (selective serotonin reuptake inhibitor) use during pregnancy and an increased risk of PPHN. SSRIs include medications like fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro).

A landmark study published in the New England Journal of Medicine (Chambers et al., 2006) found that SSRI use after 20 weeks of pregnancy was associated with a six-fold increased risk of PPHN. The absolute risk increased from approximately 1 per 1,000 to 6-12 per 1,000 births. Subsequent studies have confirmed this association, though with varying risk estimates.

The proposed mechanism involves serotonin's effect on pulmonary vascular tone. Serotonin is a potent pulmonary vasoconstrictor, and SSRIs increase serotonin levels by blocking its reuptake. Exposure of the fetal pulmonary vasculature to elevated serotonin levels in late pregnancy may prevent the normal drop in pulmonary vascular resistance at birth.

The standard of care for managing maternal depression during pregnancy includes: - Counseling about risks and benefits: Women taking SSRIs should be counseled about the potential risk of PPHN and the risks of untreated depression. The decision to continue or discontinue SSRIs should be individualized. - Consideration of alternatives: For women with mild to moderate depression, psychotherapy or non-pharmacological treatments may be appropriate alternatives. - Monitoring: Pregnant women on SSRIs should be monitored closely, and the newborn should be observed for signs of PPHN after delivery. - Informed consent: Under New York Public Health Law § 2805-d, the physician must properly inform the patient of the material risks of continuing SSRI use during pregnancy, including PPHN.

Failure to counsel a pregnant woman about the risk of PPHN associated with SSRI use — particularly after 20 weeks — may constitute lack of informed consent and may support a wrongful birth or malpractice claim if the baby develops PPHN.

Meconium Aspiration Syndrome and PPHN

Meconium aspiration syndrome (MAS) is one of the leading causes of PPHN. Meconium is the baby's first stool — a thick, greenish substance. When meconium is passed into the amniotic fluid before or during delivery, and the baby inhales it, the meconium can: - Block the airways (causing respiratory distress) - Cause chemical inflammation of the lungs (chemical pneumonitis) - Inactivate surfactant (causing lung collapse) - Cause pulmonary vasoconstriction (leading to PPHN)

The standard of care for managing meconium-stained amniotic fluid includes: - Continuous fetal monitoring: Meconium-stained fluid may indicate fetal distress. The fetal heart rate should be continuously monitored. - Assessment of meconium consistency: Thick meconium is more concerning than thin. Thick meconium may indicate more significant fetal distress. - Pediatric team presence: A pediatric or neonatal team should be present at delivery when there is thick meconium. - Assessment of the newborn: The current NRP (Neonatal Resuscitation Program) guidelines no longer recommend routine intubation and suctioning for all babies with meconium-stained fluid. Instead, only babies who are not vigorous (poor tone, poor breathing, low heart rate) require intubation and suctioning. - Monitoring for respiratory distress: All babies with meconium-stained fluid should be monitored for signs of respiratory distress, MAS, and PPHN after delivery. - Treatment of PPHN: If PPHN develops, the baby should be transferred to a NICU with capabilities for advanced respiratory support (high-frequency ventilation, inhaled nitric oxide, ECMO).

Failure to monitor appropriately, failure to recognize MAS, delay in treating PPHN, or failure to transfer to an appropriate facility — resulting in prolonged hypoxia and brain injury — may constitute negligence. [Link to: /birth-injury/meconium-aspiration-lawyer]

Symptoms and Diagnosis of PPHN

PPHN is typically apparent shortly after birth. Symptoms include: - Cyanosis: The baby appears blue despite receiving supplemental oxygen. The oxygen saturation does not improve significantly with 100% oxygen (the 'hyperoxia test'). - Respiratory distress: Rapid breathing, grunting, nasal flaring, retractions (pulling in of the chest wall). - Tachycardia: Rapid heart rate. - Differential cyanosis: If the right-to-left shunting is through the ductus arteriosus, the baby may have pink (well-oxygenated) hands and feet but blue lips and face (differential cyanosis), or vice versa depending on the shunt direction. - Low oxygen saturation: Pre-ductal (right hand) and post-ductal (foot) oxygen saturations may differ by more than 10% if there is a right-to-left ductal shunt.

Diagnosis is confirmed by: - Chest X-ray: May show normal or mildly abnormal lungs (PPHN can occur with structurally normal lungs). - Echocardiogram: The definitive diagnostic test. Shows elevated pulmonary artery pressure, right-to-left or bidirectional shunting through the ductus arteriosus or foramen ovale, and right ventricular hypertrophy. - Pre- and post-ductal oxygen saturations: A difference of more than 5-10% suggests a right-to-left ductal shunt.

Standard of Care for PPHN Management

The standard of care for managing PPHN includes: - Oxygen therapy: 100% oxygen (though prolonged high oxygen can cause lung damage and ROP). - Mechanical ventilation: To optimize oxygenation and ventilation. High-frequency ventilation (oscillator or jet) may be used for severe cases. - Inhaled nitric oxide (iNO): A selective pulmonary vasodilator that lowers pulmonary blood pressure without lowering systemic blood pressure. The standard of care for moderate to severe PPHN. - Hemodynamic support: Maintaining adequate blood pressure and cardiac output with fluids, inotropes (dopamine, dobutamine, epinephrine), and vasopressors. - Corrections of acidosis, hypoglycemia, hypothermia, and hypocalcemia: All of which can worsen pulmonary hypertension. - ECMO (Extracorporeal Membrane Oxygenation): The treatment of last resort for severe, refractory PPHN. ECMO is essentially a heart-lung bypass machine that oxygenates the blood outside the body, allowing the lungs to rest and recover. - Sedation and pain management: To minimize stress, which can worsen pulmonary hypertension.

Failure to recognize PPHN, failure to initiate appropriate treatment (including iNO and ECMO referral), or failure to transfer to a facility with ECMO capability — resulting in prolonged hypoxia and brain injury — may constitute negligence.

When PPHN Constitutes Malpractice

PPHN may give rise to a medical malpractice claim when: - Failure to counsel about SSRI risks: A pregnant woman on SSRIs was not properly informed about the risk of PPHN. - Failure to monitor for fetal distress: Signs of meconium aspiration or asphyxia were not recognized or acted upon. - Delayed cesarean delivery: When there were signs of fetal distress that warranted cesarean, and the delay caused or contributed to perinatal asphyxia and PPHN. - Failure to manage meconium aspiration: The meconium was not properly managed during delivery, causing MAS and subsequent PPHN. - Delayed diagnosis of PPHN: PPHN was not recognized promptly after birth, delaying treatment. - Failure to use inhaled nitric oxide: iNO is the standard of care for moderate to severe PPHN. Failure to use iNO when indicated is a deviation. - Failure to transfer for ECMO: When PPHN is refractory to conventional treatment, the baby should be transferred to an ECMO-capable facility. Failure to transfer in a timely manner may constitute negligence. - Inadequate monitoring: Failure to monitor oxygenation, blood pressure, and acid-base status adequately.

Consequences of PPHN

Even with treatment, PPHN can cause devastating consequences: - Hypoxic-ischemic encephalopathy (HIE): Prolonged hypoxia can cause brain damage. [Link to: /medical-malpractice/hie-claims] - Cerebral palsy: Hypoxic brain injury can lead to cerebral palsy. - Developmental delays and cognitive impairment: Hypoxia affects brain development. - Seizures: Hypoxic brain injury can cause epilepsy. - Hearing loss: PPHN survivors are at increased risk of sensorineural hearing loss. - Chronic lung disease: Prolonged ventilation can cause bronchopulmonary dysplasia (BPD). - Death: PPHN has a 10-20% mortality rate even with treatment.

New York Statute of Limitations

Under CPLR § 214-a, the statute of limitations is 2.5 years. The infancy toll (CPLR § 208) extends the child's deadline to age 20. Parents' economic claims must be filed within 2.5 years. For municipal hospital claims, a Notice of Claim must be filed within 90 days (GML § 50-e). [Link to: /birth-injury/statute-of-limitations]

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.